Unlock Hidden Value: Invest in Pfizer Today
Pfizer is a leading pharmaceutical and biotechnology company. They develop and produce medicines and vaccines for various medical fields, including immunology, oncology, cardiology, endocrinology, and neurology. Pfizer has a robust global manufacturing infrastructure with 35+ manufacturing sites and 300+ external suppliers, reaching over 180 countries. Their operations are known for their agility, resilience, and commitment to quality and safety.
Financial Performance and Ratios
As of 2023, Pfizer reported revenues of $58.5 billion, with an operating income of $2.17 billion and a net income of $2.12 billion. Key financial ratios include: Price-to-Earnings (PE) Ratio: 34.58; Price-to-Sales (PS) Ratio: 2.49; Price-to-Book (PB) Ratio: 1.60; Debt-to-Equity Ratio: 0.73; Return on Equity (ROE): 4.54%; Return on Assets (ROA): 3.31%; Dividend Yield: 6.53%.
Pfizer Stock Price Performance
Pfizer’s stock price has seen fluctuations over the years. As of December 10, 2024, the stock price is $25.57, with a 52-week high of $31.54 and a low of $24.48. The stock has experienced a decline of about 11.98%.
Investment Insight
As a leading biotechnology and pharmaceutical company, Pfizer may not have the highest Investment Scoreboard. However, this does not preclude it from generating substantial returns for shareholders. Particularly now, with the stock price having dropped significantly, there is a promising opportunity. The 10-year compound annual growth rate (CAGR) is -1.59%, indicating that purchasing shares now could yield up to a 20% return from stock price growth alone.
Pfizer Stock Forecast**
| MIN/MAX | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| MIN | 55.38 | 56.81 | 58.27 | 59.77 | 61.31 |
| MAX | 71.35 | 73.19 | 75.08 | 77.01 | 79.00 |
When to buy?
The Double Bottom patern presents a prime opportunity to purchase stocks at a low price. This is an excellent market entry point for investors looking to add this company’s shares to their portfolio.
Dividend Policy
Pfizer has a consistent dividend policy, with a current dividend yield of 6.53%. The company has a payout ratio of 225.68%, indicating that it pays out more in dividends than its earnings. Pfizer’s commitment to returning value to shareholders is evident in its regular dividend payments.
Conclusion
Pfizer, a leading pharmaceutical and biotechnology company, maintains a robust global manufacturing infrastructure and a commitment to quality and safety. Despite a recent decline in stock price, the company shows potential for significant returns. The Double Bottom pattern indicates a prime buying opportunity for investors. With a consistent dividend policy, Pfizer remains a compelling investment option, though its current valuation suggests caution.
A cup of coffee from you for this excellent analysis.
Company’s Site.
More US Stocks.
*Investment analysis involves scrutinizing over 50 different criteria to assess a company's ability to generate shareholder value. This comprehensive approach includes tracking revenue, profit, equity dynamics, dividend payments, cash flow, debt and financial management, stock price trends, bankruptcy risk, F-Score, and more. These metrics are consolidated into a straightforward Investment Scoreboard, which effectively helps predict future stock price movements.
**Use the price forecast to manage the risk of your investments.